Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP022: Tacrolimus suppositories as induction therapy for refractory ulcerative proctitis: a randomised controlled trialECCO '18 Vienna
Year: 2018
Authors:

J.E. Kreijne1*, M.R. Lie1, G. Dijkstra2, M. Löwenberg3, G. van Assche4, R.L. West5, D. van Noord5, A.A. van der Meulen - de Jong6, B.E. Hansen1,7, A.C. de Vries1, C.J. van der Woude1

1Erasmus MC, Gastroenterology and Hepatology, Rotterdam, The Netherlands, 2University Medical Center Groningen and University of Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands, 3Academic Medical Center Amsterdam, Gastroenterology and Hepatology, Amsterdam, The Netherlands, 4University Hospitals Leuven, KU Leuven, Gastroenterology, Leuven, Belgium, 5Franciscus Hospital and Vlietland Hospital, Gastroenterology and Hepatology, Rotterdam, The Netherlands, 6Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, The Netherlands, 7Toronto General Hospital, Center for Liver Disease, Toronto, Canada

DOP023: Tofacitinib for the treatment of ulcerative colitis: up to 4.4 years of safety data from global clinical trialsECCO '18 Vienna
Year: 2018
Authors:

W.J. Sandborn1, J. Panés2*, G.R. D’Haens3, B.E. Sands4, C. Su5, M. Moscariello5, T.V. Jones5, R.D. Pedersen5, G.S. Friedman5, N. Lawendy5, G. Chan5

1University of California San Diego, Division of Gastroenterology, La Jolla, CA, USA, 2Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, 3Academic Medical Centre, Department of Gastroenterology, Amsterdam, The Netherlands, 4Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, NY, USA, 5Pfizer Inc., Collegeville, PA, USA

DOP024: Tofacitinib achieves symptomatic improvement within 3 days in moderately to severely active ulcerative colitis, regardless of prior tumour necrosis factor inhibitor treatment status: results from OCTAVE induction 1 and 2ECCO '18 Vienna
Year: 2018
Authors:

S. Hanauer1, R. Panaccione2, S. Danese3, A. Cheifetz4, W. Reinisch5*, P.D.R. Higgins6, D.A. Woodworth7, H. Zhang7, G.S. Friedman7, N. Lawendy7, D. Quirk7, C.I. Nduaka7, C. Su7

1Northwestern University, Evanston, IL, USA, 2University of Calgary, Calgary, AB, Canada, 3Humanitas Research Hospital, IBD Center, Department of Gastroenterology, Rozzano, Milan, Italy, 4Beth Israel Deaconess Medical Center and Harvard Medical School, Department of Medicine and Division of Gastroenterology, Boston, MA, USA, 5Medical University of Vienna, Department of Internal Medicine III, Vienna, Austria, 6University of Michigan, Ann Arbor, MI, USA, 7Pfizer Inc., Collegeville, PA, USA

DOP025: Tofacitinib for the treatment of ulcerative colitis: analysis of malignancy rates from the OCTAVE clinical programmeECCO '18 Vienna
Year: 2018
Authors:

G.R. Lichtenstein1, M.A. Ciorba2, G. Rogler3*, D. Quirk4, C.I. Nduaka4, R.D. Pedersen4, N. Lawendy4, G. Chan4, C. Su4, J. Panés5

1Perelman School of Medicine of the University of Pennsylvania, Division of Gastroenterology, Philadelphia, PA, USA, 2Washington University in Saint Louis, Division of Gastroenterology, Saint Louis, MO, USA, 3University of Zürich, Department of Gastroenterology and Hepatology, Zürich, Switzerland, 4Pfizer Inc., Collegeville, PA, USA, 5Hospital Clínic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain

DOP026: Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE openECCO '18 Vienna
Year: 2018
Authors:

B.E. Sands1, A.C. Moss2, A. Armuzzi3*, J.K. Marshall4, J.O. Lindsay5, W.J. Sandborn6, S. Danese7, K. Tsilkos8, N. Lawendy9, H. Zhang9, G.S. Friedman9, G. Chan9, D.W. Krichbaum8, C. Su9

1Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, NY, USA, 2Beth Israel Deaconess Medical Centre, Division of Gastroenterology, Boston, MA, USA, 3Presidio Columbus Fondazione Policlinico Gemelli Università Cattolica, IBD Unit, Rome, Italy, 4McMaster University, Division of Gastroenterology, Department of Medicine, Farncombe Family Digestive Health Research Institute, Hamilton, ON, Canada, 5The Royal London Hospital, Barts Health NHS Trust, Department of Gastroenterology, London, UK, 6University of California San Diego, Division of Gastroenterology, La Jolla, CA, USA, 7Humanitas Research Hospital, IBD Center, Department of Gastroenterology, Rozzano, Milan, Italy, 8Pfizer Inc., New York, NY, USA, 9Pfizer Inc., Collegeville, PA, USA

DOP027: Efficacy and safety of an additional 8 weeks of tofacitinib induction therapy: Results of the OCTAVE open study for tofacitinib 8-week induction non-respondersECCO '18 Vienna
Year: 2018
Authors:

B.G. Feagan1, M.C. Dubinsky2, M. Lukas3*, D. Quirk4, C.I. Nduaka4, E. Maller4, N. Lawendy4, C. Kayhan4, W. Wang4, G. Chan4, C. Su4

1Western University, Robarts Clinical Trials, London, ON, Canada, 2Icahn School of Medicine at Mount Sinai Hospital, Department of Pediatrics and Medicine, New York, NY, USA, 3Charles University, Prague, Czech Republic, 4Pfizer Inc., Collegeville, PA, USA

DOP028: Second N-ECCO Consensus Statements on the European nursing roles in caring for patients with Crohn’s disease or ulcerative colitisECCO '18 Vienna
Year: 2018
Authors:

K. Kemp1*, L. Dibley2, U. Chauhan3, K. Greveson4, S. Jaghult5, K. Ashton6, S. Buckton7, J. Duncan8, P. Hartmann9, N. Ipenburg10, L. Moortgat11, R. Theeuwen12, M. Verway13, L. Younge14, P. Bager15

1Manchester Royal Infirmary/University of Manchester, Gastroenterology, Manchester, UK, 2University of Greenwich/Barts Heath, School of Nursing/Gastroenterology, London, UK, 3McMasterUniversity, Digestive Diseases, Hamilton, Canada, 4Royal Free Hospital, Gastroenterology, London, UK, 5Karolinska Institutet Danderyd Hospital, Stockholm Gastro Centre, Stockholm, Sweden, 6Hull and East Yorkshire Hospitals, Gastroenterology, Hull, UK, 7Coastal Digestive Health, IBD Clinic, Mountain Creek, Australia, 8St Thomas' Hospital, Gastroenterology, London, UK, 9Gastroenterologische Gemeinschaftspraxis, Gastroenterology, Minden, Germany, 10Ijsselland Hospital, Department of Surgery, ZC Capelle A/D Ijssel, The Netherlands, 11AZ Delta Roeselare-Menen, Gastroenterology, Roeselare, Belgium, 12LUMC, Gastroenterology, Leiden, The Netherlands, 13Leiden University Medical Centre, Gastroenterology, Leiden, The Netherlands, 14Barts and The London NHS Trust, Gastroenterology, London, UK, 15Gastroenterology and Hepatology Aarhus University, Department of Medicine, Aarhus, Denmark

DOP029: Treatment and long-term outcomes of paediatric patients with penetrating Crohn’s diseaseECCO '18 Vienna
Year: 2018
Authors:

L. Kollen1, A. Leroyer2, A. Breton3, M. Fumery4, G. Savoye5, J. Lemale6, D. Morin1, B. Pariente7, E. Mas3, D. Turck8, M. Al Khouri1, P. Blanc9, C. Gower2, G. Pineton de Chambrun9*

1Montpellier University Hospital, Pediatric Gastroenterology and Nutrition, Montpellier, France, 2Lille University Hospital, Epidemiology, Lille, France, 3Toulouse University Hospital, Pediatric Gastroenterology and Nutrition, Toulouse, France, 4Amiens University Hospital, Gastroenterology, Amiens, France, 5Rouen University Hospital, Gastroenterology, Rouen, France, 6Armand Trousseau University Hospital, Pediatric Gastroenterology and Nutrition, Paris, France, 7Lille University Hospital, Gastroenterology, Lille, France, 8Lille University Hospital, Pediatric Gastroenterology and Nutrition, Lille, France, 9Montpellier University Hospital, Gastroenterology, Montpellier, France

DOP030: The efficacy of home telemonitoring vs. conventional follow-up: a randomised controlled trial among teenagers with inflammatory bowel diseaseECCO '18 Vienna
Year: 2018
Authors:

A. Heida1, A. Muller Kobold2, J. Rossen3, A. Kindermann4, F. Kokke5, T. Meij, De6, O. Norbruis7, R. Weersma8, M. Wessels9, T. Hummel10, H. Escher11, H. Wering, van12, D. Hendriks13, L. Mearin14, H. Groen15, H. Verkade1, P. Van Rheenen1*

1University Medical Center Groningen, Paediatric Gastroenterology Hepatology and Nutrition, Groningen, The Netherlands, 2University Medical Center Groningen, Laboratory Medicine, Groningen, The Netherlands, 3University Medical Center Groningen, Microbiology, Groningen, The Netherlands, 4Academic Medical Center, Paediatric Gastroenterology Hepatology and Nutrition, Amsterdam, The Netherlands, 5Wilhemina Kinder Ziekenhuis, Paediatric Gastroenterology Hepatology and Nutrition, Utrecht, The Netherlands, 6VU Medical Center, Paediatric Gastroenterology Hepatology and Nutrition, Amsterdam, The Netherlands, 7Isala Clinic, Paediatrics, Zwolle, The Netherlands, 8University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands, 9Rijnstate Hospital, Paediatrics, Arnhem, The Netherlands, 10Medisch Spectrum Twente, Paediatrics, Enschede, The Netherlands, 11Erasmus Medical Center – Sophia Kinder Ziekenhuis, Paediatric Gastroenterology Hepatology and Nutrition, Rotterdam, The Netherlands, 12Amphia Ziekenhuis, Paediatrics, Breda, The Netherlands, 13Haga Hospital, Paediatrics, The Hague, The Netherlands, 14Leiden University Medical Center, Paediatric Gastroenterology Hepatology and Nutrition, Leiden, The Netherlands, 15University Medical Center Groningen, Epidemiology, Groningen, The Netherlands

DOP031: Individualised home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended implemented in clinical practiceECCO '18 Vienna
Year: 2018
Authors:

D.V. Ankersen*, D. Marker, P. Weimers, J. Burisch, P. Munkholm

North Zealand University Hospital, Frederikssund, Denmark

DOP032: Crohn’s disease patients’ perspectives towards de-escalating immunosuppressive therapy: a comparative French and American surveyECCO '18 Vienna
Year: 2018
Authors:

C.A. Siegel1*, K.D. Thompson2, D. Walls3, J. Gollins4, A. Buisson5, A. Olympie5, L. Beaugerie6, J.-F. Colombel7, E. Louis on behalf of the BIOCYCLE group8

1Dartmouth-Hitchcock Medical Center, Lebanon, USA, 2Dartmouth-Hitchcock Medical Center, Medicine, Lebanon, USA, 3BDJ Solutions, Boston, USA, 4Delta Modelling, Chicago, USA, 5Association François Aupetit, Paris, France, 6Hôpital Saint-Antoine, Paris, France, 7Icahn School of Medicine at Mount Sinai, New York, USA, 8University Hospital CHU of Liège, Liège, Belgium

DOP033: Trends in epidemiology of inflammatory bowel disease among Jewish Israeli adolescents: a population-based studyECCO '18 Vienna
Year: 2018
Authors:

I. Ghersin1*, L.H. Katz2, S. Daher3, R. Shamir4, A. Assa4

1Rambam Health Care Campus, Haifa, Israel, 2Sheba Medical Center, Gastroenterology, Ramat Gan, Israel, 3IDF Medical Corps, Tel Hashomer, Israel, 4Schneider Children's Medical Center, Gastroenterology, Petach Tikva, Israel

DOP034: Assessment of direct healthcare cost drivers of Crohn’s disease in a Dutch population-based cohort study shows a major shiftECCO '18 Vienna
Year: 2018
Authors:

R. Lalisang1*, D. Wintjens1,2, M. Romberg-Camps3, A. van Bodegraven3, L. Oostenbrug3, J. Haans1, A. Masclee1,2, D. Jonkers1,2, M. Pierik1,2

1Maastricht University Medical Centre, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht, The Netherlands, 2Maastricht University Medical Centre, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht, The Netherlands, 3Zuyderland Medical Centre, Department of Gastroenterology and Hepatology, Sittard-Geleen/Heerlen, The Netherlands

DOP035: Beclomethasone dipropionaat is effective for microscopic colitis: results of an open-label multicentre study (COLCO)ECCO '18 Vienna
Year: 2018
Authors:

T. De Corte1, E. Janssens1*, K. Thorrez2, A. D'Hondt1, K. Dejaegher3, F. D'Heygere4, B. van Besien2, L. Harlet1, H. Peeters5, W. Vanmoerkercke4, P. van Hootegem6, F. Baert1

1AZ Delta Roeselare Menen, Department of Gastroenterology, Roeselare, Belgium, 2Jan Yperman Hospital, Department of Gastroenterology, Ieper, Belgium, 3Sint-Jozefskliniek, Department of Gastroenterology, Izegem, Belgium, 4AZ Groeninge, Department of Gastroenterology, Kortrijk, Belgium, 5AZ St. Lucas, Department of Gastroenterology, Ghent, Belgium, 6AZ St. Lucas, Department of Gastroenterology, Brugge, Belgium

DOP036: Ustekinumab for Crohn’s disease: a nationwide real-life observational cohort study (ICC case series)ECCO '18 Vienna
Year: 2018
Authors:

V. Biemans1,2*, A. van der Meulen - de Jong3, C. van der Woude4, N. de Boer5, G. Dijkstra6, B. Oldenburg7, C. Ponsioen8, P. Maljaars3, J. Haans2, M. Pierik2, F. Hoentjen9, Dutch Initiative on Crohn and Colitis (ICC)

1Radboudumc, Nijmegen, The Netherlands, 2Maastricht University Medical Center (MUMC), Maastricht, The Netherlands, 3Leiden University Medical Center (LUMC), Department of Gastroenterology and Hepatology, Leiden, The Netherlands, 4Erasmus Medical Center, Rotterdam, The Netherlands, 5VU University Medical Centre Institute of Education, Department of Gastroenterology and Hepatology, Room J393, Amsterdam, The Netherlands, 6University Medical Center Groningen, Groningen, The Netherlands, 7University Medical Centre Utrecht, Utrecht, The Netherlands, 8Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands, 9Radboudumc, Department of Gastroenterology and Hepatology, Nijmegen, The Netherlands

DOP037: Postoperative anti-TNF therapy is associated with a significant reduction of both endoscopic and clinical recurrence following surgery for ileocolonic Crohn’s disease: results of a prospective nationwide cohort conducted by the GETAID chirurgie groupECCO '18 Vienna
Year: 2018
Authors:

L. Maggiori1*, A. Brouquet2, P. Zerbib3, J. Lefevre4, Q. Denost5, A. Germain6, E. Cotte7, L. Beyer-Berjot8, N. Munoz-Bongrand9, V. Desfourneaux10, A. Rahili11, J.-P. Duffas12, K. Pautrat13, C. Denet14, V. Bridoux15, G. Meurette16, J.-L. Faucheron17, J. Loriau18, F. Guillon19, E. Vicaut20, Y. Panis1, S. Benoist2

1Beaujon Hospital, APHP, Colorectal Surgery, Clichy, France, 2CHU Bicetre, APHP, Department of Oncologic and Digestive Surgery, Le Kremlin-Bicetre, France, 3CHRU Lille, Department of Digestive Surgery and Transplantation, Lille, France, 4St Antoine Hospital, APHP, Digestive Surgery, Paris, France, 5CHU Bordeaux, Digestive Surgery, Bordeaux, France, 6CHRU Nancy, Digestive Surgery, Nancy, France, 7CHU Lyon-Sud, Digestive Surgery, Lyon, France, 8CHU Marseille-Nord, Digestive Surgery, Marseille, France, 9St Louis Hospital, APHP, Digestive Surgery, Paris, France, 10CHU Rennes, Digestive Surgery, Rennes, France, 11CHU Nice, Digestive Surgery, Nice, France, 12CHU Toulouse, Digestive Surgery, Toulouse, France, 13Lariboisière Hospital, APHP, Digestive Surgery, Paris, France, 14Institut Mutualiste Montsouris, Digestive Surgery, Paris, France, 15CHU Rouen, Digestive Surgery, Rouen, France, 16CHU Nantes, Digestive Surgery, Nantes, France, 17CHU Grenoble, Digestive Surgery, Grenoble, France, 18Hopital St Joseph, Digestive Surgery, Paris, France, 19CHU Montpellier, Digestive Surgery, Montpellier, France, 20Lariboisière Hospital, APHP, Departement of Clinical Research, Paris, France

DOP039: Exploring stoma rates in Crohn’s disease in the biologic era: a population-based time trend analysisECCO '18 Vienna
Year: 2018
Authors:

C. Ma*, P.G. Kotze, A. Almutairdi, D. Tanyngoh, C. Seow, K. Novak, C. Lu, R. Panaccione, G. Kaplan

University of Calgary, IBD Unit, Division of Gastroenterology and Hepatology, Calgary, Canada

DOP040: Five-year colectomy data from the observational postmarketing ulcerative colitis study, a European registry for adults with ulcerative colitis treated with originator infliximab or conventional therapyECCO '18 Vienna
Year: 2018
Authors:

J. Panés1*, J.O. Lindsay2, N. Teich3,4, S. Lindgren5, J.-F. Colombel6, F. Cornillie7, H. Ann Flynn8, S. Huyck8, P. Stryszak8, R. Yao8, G. Philip8, W. Reinisch9

1Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, 2The Royal London, Barts Health NHS Trust, London, UK, 3Internistische Gemeinschaftspraxis, Leipzig, Germany, 4Faculty of Medicine, Jena University, Jena, Germany, 5Lund University, Malmo, Sweden, 6Icahn School of Medicine at Mount Sinai, New York, USA, 7Merck Sharpe and Dohme, Kriens, Switzerland, 8Merck & Co., Inc., Kenilworth, USA, 9Universitätsklinik für Innere Medizin III, Vienna, Austria

DOP041: Surgery and hospitalisation in patients with inflammatory bowel disease; 10-year follow-up of a Danish population-based inception cohortECCO '18 Vienna
Year: 2018
Authors:

B. Lo1*, I. Vind1, F. Bendtsen1, M. Vester-Andersen1,2, J. Burisch1

1Copenhagen University Hospital Hvidovre, The Gastro Unit, Medical Division, Hvidovre, Denmark, 2Zealand University Hospital, Medical Department, Køge, Denmark